Drugs / Tolerogenic Dendritic cells loaded with myelin peptides
Tolerogenic Dendritic cells loaded with myelin peptides
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02283671 | Sep 2015 → Jul 2019 | multiple sclerosis, neuromyelitis optica | Sara Varea | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tolerogenic Dendritic cells loaded with myelin peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02283671 ↗ |
| Modality | Cell therapy | “Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.” NCT02283671 ↗ |
| Route | Intravenous | “Patients will receive intravenous administration every two weeks” NCT02283671 ↗ |